Effects of cytokines and chemokines on migration of mesenchymal stem cells following spinal cord injury

Longyun Li, Maoguang Yang, Chunxin Wang, Qiheng Zhao, Jian Liu, Chuanguo Zhan, Zhi Liu, Xuepeng Li, Weihua Wang, Xiaoyu Yang

Abstract

We investigated the effects of cytokines and chemokines and their associated signaling pathways on mesenchymal stem cell migration following spinal cord injury, to determine their roles in the curative effects of mesenchymal stem cells. This study reviewed the effects of tumor necrosis factor-α, vascular endothelial growth factor, hepatocyte growth factor, platelet-derived growth factor, basic fibroblast growth factor, insulin-like growth factor-1, stromal cell-derived factor and monocyte chemoattractant protein-1 during mesenchymal stem cell migration to damaged sites, and analyzed the signal transduction pathways involved in their effects on mesenchymal stem cell migration. The results confirmed that phosphatidylinositol 3-kinase and nuclear factor-κB play crucial roles in the migration of mesenchymal stem cells induced by cytokines and chemokines.

Key Words

spinal cord injury; mesenchymal stem cells; migration; cytokine; chemokine; signaling pathway; neural regeneration

INTRODUCTION

Recent studies have focused on mesenchymal stem cells (MSCs) for the treatment of spinal cord injuries (SCIs). However, it is necessary to increase MSC migration to damaged sites and numbers of MSCs at the damaged sites in order to realize the therapeutic effects of MSC transplantation. A previous study found that the expression levels of various cytokines and chemokines were upregulated after SCI. MSCs express cytokine and chemokine receptors that participate in signal transduction pathways during MSC migration. However, the precise relationship between the various cytokines and chemokines and MSC migration remains unclear. The present study reviewed the relationships between cytokines and chemokines and MSC migration, and examined the signal transduction mechanisms activated after SCI, to inform subsequent research into MSC migration mechanisms and SCI treatment.

EFFECTS OF CYTOKINES ON MSC MIGRATION AFTER SCI

Tumor necrosis factor-α (TNF-α)

TNF-α is an important proinflammatory cytokine that plays a crucial role in the immune response and inflammation. In the context of SCI, TNF-α is produced by immune cells and mediates various proinflammatory effects, such as the recruitment of immune cells to the injured site, the induction of proinflammatory cytokines, and the promotion of tissue damage. The role of TNF-α in promoting MSC migration after SCI has been studied extensively. Recent studies have shown that TNF-α can enhance the migration of human MSCs in vitro. TNF-α can interact with its receptor on MSCs and activate various signaling pathways, such as the NF-κB and MAPK pathways, which promote cell migration.

Vascular endothelial growth factor (VEGF)

VEGF is a potent angiogenic factor that plays a crucial role in the regulation of blood vessel formation and growth. In the context of SCI, VEGF is produced by various cell types, such as astrocytes and neurons, and promotes the survival and migration of both MSCs and neural progenitor cells. VEGF also induces angiogenesis, which is critical for the repair of damaged tissue. Studies have shown that VEGF increases the migration of human MSCs and promotes the formation of neo-vascular structures in vitro.

Hepatocyte growth factor (HGF)

HGF is a potent mitogenic and motogenic factor that promotes cell survival and migration. In the context of SCI, HGF is produced by glial cells and promotes the survival and migration of both MSCs and neural progenitor cells. HGF also induces the proliferation of astrocytes and neuromasts, which are critical for the repair of damaged tissue. Recent studies have shown that HGF enhances the migration of human MSCs in vitro.

Platelet-derived growth factor (PDGF)

PDGF is a potent mitogenic and motogenic factor that promotes cell survival and migration. In the context of SCI, PDGF is produced by various cell types, such as astrocytes and neurons, and promotes the survival and migration of both MSCs and neural progenitor cells. PDGF also induces angiogenesis, which is critical for the repair of damaged tissue. Studies have shown that PDGF increases the migration of human MSCs and promotes the formation of neo-vascular structures in vitro.

Basic fibroblast growth factor (bFGF)

bFGF is a potent mitogenic and motogenic factor that promotes cell survival and migration. In the context of SCI, bFGF is produced by various cell types, such as astrocytes and neurons, and promotes the survival and migration of both MSCs and neural progenitor cells. bFGF also induces angiogenesis, which is critical for the repair of damaged tissue. Studies have shown that bFGF enhances the migration of human MSCs in vitro.

Insulin-like growth factor-1 (IGF-1)

IGF-1 is a potent mitogenic and motogenic factor that promotes cell survival and migration. In the context of SCI, IGF-1 is produced by various cell types, such as astrocytes and neurons, and promotes the survival and migration of both MSCs and neural progenitor cells. IGF-1 also induces angiogenesis, which is critical for the repair of damaged tissue. Studies have shown that IGF-1 enhances the migration of human MSCs in vitro.

Monocyte chemoattractant protein-1 (MCP-1)

MCP-1 is a potent chemoattractant factor that promotes the recruitment of immune cells to the injured site. In the context of SCI, MCP-1 is produced by various cell types, such as astrocytes and neurons, and promotes the infiltration of immune cells. MCP-1 also enhances the migration of human MSCs in vitro.

Phosphatidylinositol 3-kinase (PI3K)

PI3K is a key enzyme in the regulation of cell survival and migration. In the context of SCI, PI3K is activated by various growth factors, such as PDGF, bFGF, and IGF-1, and promotes the migration of MSCs. Recent studies have shown that PI3K inhibitors can block the migration of human MSCs in vitro.

Nuclear factor-κB (NF-κB)

NF-κB is a transcription factor that plays a crucial role in the regulation of inflammation and immune response. In the context of SCI, NF-κB is activated by various proinflammatory cytokines, such as TNF-α, and promotes the migration of MSCs. Studies have shown that NF-κB inhibitors can block the migration of human MSCs in vitro.

Abbreviations

SCI: spinal cord injury; MSCs: mesenchymal stem cells; PI3K: phosphatidylinositol 3-kinase; NF-κB: nuclear factor-κB; TNF-α: tumor necrosis factor-α; SDF-1: stromal cell-derived factor-1; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor; HGF: hepatocyte growth factor; bFGF: basic fibroblast growth factor; IGF-1: insulin-like growth factor-1; MCP: monocyte chemoattractant protein

Received: 2012-01-18
Accepted: 2012-03-20
(N20111122003/WLM)

www.nrronline.org

doi:10.3969/j.issn.1673-5374.2012.14.010
factor that is rapidly induced in local regions after SCI\textsuperscript{7}. TNF-α induces neuronal apoptosis, and early and immediate inhibition of TNF-α expression therefore relieved pathological changes in the spinal cord and improved functional disturbance\textsuperscript{9}. In contrast, Pan et al\textsuperscript{9} found that TNF-α improved neurological function of the spinal cord, associated with a specific time window of TNF-α upregulation. A study of TNF-α protein and mRNA levels confirmed that human MSCs express TNF-α receptors\textsuperscript{10}, and that the combination of TNF-α and its receptor enhanced the adhesion of human MSCs and vascular endothelial cells, as well as the targeted-migration ability of human MSCs\textsuperscript{11}. TNF-α is therefore believed to contribute to the induction of targeted migration of MSCs towards damaged sites in the spinal cord.

Another study\textsuperscript{12} demonstrated that TNF-α activated the extracellular signal-regulated kinase and p38 pathways in MSCs, accelerated intranuclear genetic transcription and protein synthesis, and promoted MSC migration activity by combining with MSC surface receptors. In addition, TNF-α activated inhibitor protein kB (IB) kinase/IB/nuclear factor-κB (NF-κB), accelerated intranuclear genetic transcription and protein synthesis, and strengthened MSC migration ability\textsuperscript{13}. CC chemokine receptor expression levels were upregulated and interactions with ligands were reinforced in the presence of TNF-α\textsuperscript{14}. CXC-chemokine receptor 4 (CXCR4) expression was unaffected by TNF-α, but TNF-α promoted MSC migration by enhancing its sensitivity to stromal cell-derived factor-1 (SDF-1)\textsuperscript{14}. Further studies are needed to determine if TNF-α enhances MSC migration by directly activating intracellular signal cascade reactions, rather than by enhancing interactions between other factors/receptors.

**Vascular endothelial growth factor (VEGF)**

VEGF is a homodimeric glycoprotein that increases MSC transplantation efficiency after ischemic injury\textsuperscript{10}. Liu et al\textsuperscript{15} found that VEGF-A was highly expressed in ischemic central nervous system, and improved the recovery of spinal cord function. VEGF-A is a highly-active member of the VEGF family, which has been shown to enhance human MSC migration\textsuperscript{16}. The promotional effects of VEGF-A on the recovery of neurological function of the spinal cord may therefore be associated with stimulation of the migration of MSCs to the damaged region. However, VEGF receptors have not been found on the surface of human MSCs; VEGF and platelet-derived growth factor (PDGF) exert their effects via PDGF receptors\textsuperscript{16-17}. VEGF and PDGF are derived from different branches of the same ancestor, and VEGF can exert its effects after combining with the PDGF receptor\textsuperscript{16}. Ball et al\textsuperscript{16} indicated that PDGF family homodimers or heterodimers participate in the VEGF-A/PDGF signaling pathway. Moreover, the combination of PDGF and VEGF was more effective at mediating bone marrow MSC migration compared to either PDGF or VEGF alone\textsuperscript{16}. Lee et al\textsuperscript{18} reported that VEGF combined with Src stimulated focal adhesion kinase phosphorylation, while focal adhesion kinase also stimulated Src phosphorylation, which finally activated a downstream signaling cascade reaction. The non-receptor tyrosine kinase, Src, regulates cytoskeletal reorganization, cell adhesion, and migration.

**Hepatocyte growth factor (HGF)**

Expression levels of HGF and its receptor c-met are upregulated following SCI\textsuperscript{19}, and contribute to the recovery of spinal cord function\textsuperscript{20}. An in vitro study by Son et al\textsuperscript{21} verified that HGF regulated MSC migration by c-met and exerted chemotactic effects. Upregulated HGF expression therefore contributed to the migration of MSCs to the damaged region. Royal et al\textsuperscript{22} suggested that the small G-protein Ras-phosphatidylinositol 3-kinase (PI3K) pathway directly controlled Rac and p21-activated kinase and induced cytoskeletal reorganization following HGF-triggered signaling cascade reactions in MSCs. HGF increased Rac1 activity in a Ca\textsuperscript{2+}-dependent manner\textsuperscript{23}, while Rac1 facilitated lamellipodia formation\textsuperscript{24}, and accelerated MSC migration by stimulating the Wiskott-Aldrich syndrome protein family verprolin-homologous protein. HGF also promoted c-met phosphorylation, and these activated receptors could then activate PI3K/Akt pathway\textsuperscript{25}, resulting in cell migration. Regulation of the HGF/PI3K/Rac1/ signaling pathway may thus represent a target for enhancing MSC migration and improving its curative effects.

**PDGF**

PDGF comprises four subtypes: PDGF-A, -B, -C and -D. PDGF receptor tyrosine kinase contains PDGF-Rα and PDGF-Rβ, composed of homodimers or heterodimers. PDGF-A and PDGF-B exist as dimers and exert their effects by combining with their corresponding receptors\textsuperscript{26}. Wu et al\textsuperscript{27} found that PDGF expression was significantly elevated and exerted neuroprotective effects at 7 days following SCI, consistent with the results of another previously published study\textsuperscript{28}. Hata et al\textsuperscript{29} verified that upregulation of PDGF-B expression contributed to targeted migration of human MSCs. Upreregulated PDGF-B expression could thus induce MSC migration to damaged regions of the spinal cord. Kang et al\textsuperscript{30} thought that PDGF-B activated c-Jun NH\textsubscript{2}-terminal kinases in MSCs, resulting in phosphorylation of the transcription factor c-jun. The
targeted migration ability of human MSCs was strengthened by regulating some genetic transcription processes, but the precise mechanisms were not investigated. Ligand-stimulated and activated PDGF receptors could stimulate PI3K and activate small G-protein family Rac. The combined effects of Rac and Cdc42 led to cytoskeletal changes, and controlled the speed and direction of cell migration. The above results may be associated with the activation of actin-related proteins 2/3 and actin polymerization after combination of Cdc42 with Wiskott-Aldrich syndrome protein. PDGF may thus induce MSC migration to damaged regions via PDGF-B c-Jun NH₂-terminal kinases/c-jun and PDGF-Pi3K-Rac/Cdc42/Wiskott-Aldrich syndrome protein-actin-related proteins 2/3 pathways.

**Basic fibroblast growth factor (bFGF)**
SCI rapidly and significantly increased bFGF expression, activated a cascade reaction, and promoted the recovery of spinal cord function after SCI. Schmidt et al. observed significant bFGF-induced human MSC migration, while Liu et al. verified that the number of MSCs highly expressing bFGF after SCI was significantly increased compared to the control group, suggesting that bFGF contributed to the targeted migration of MSCs. Concentration-gradient experiments confirmed that low concentrations of bFGF suppressed MSC migration, while high concentrations promoted MSC migration; when the concentration was continuously increased, the migration activity of human MSCs fell to the initial level. bFGF activates FGF receptors, which trigger PI3K/Akt signaling and an increase in Akt and phosphoAkt. These results indicate that bFGF induces human MSC migration via a FGFR/PI3K/Akt pathway.

**Insulin-like growth factor-1 (IGF-1)**
Increased expression of IGF-1 after SCI has been shown to promote the recovery of neurological functions, suppress neuronal apoptosis, and reduce the inflammatory reaction. Baek et al. reported that IGF-1 mediated MSC migration, which may explain its effect on the recovery of neurological functions. Haider et al. confirmed that transplantation of MSCs expressing high levels of IGF-1 resulted in elevated SDF-1α and phosphorylated Akt levels. IGF-1 increased the expression levels of CXCR4, strengthened the MSC response to SDF-1 through the PI3K/Akt pathway, and increased cell migration ability. Thus although there was no evidence that IGF-1 directly induced MSC migration, it was able to increase SDF-1/CXCR4 chemotaxis and control MSC migration via PI3K/Akt.

### EFFECTS OF CHEMOKINES ON MSC MIGRATION AFTER SCI

**SDF-1**
Knerlich-Lukoschus et al. found that SDF-1 and CXCR4 were persistently highly expressed within 2–42 days after SCI. SDF-1 and CXCR4 mediated the migration ability of hematopoietic stem cells and hematopoietic progenitor cells. Numerous studies have verified the chemotactic effects of SDF-1/CXCR4 during MSC migration. Tysseling et al. demonstrated that SDF-1 induced the migration of CXCR4-positive macrophages to damaged regions following SCI, and several studies have verified that SDF-1/CXCR4 regulates MSC migration to damaged sites in the central nervous system. These results suggest that SDF-1/CXCR4 can mediate MSC migration to SCI regions. Wynn et al. reported that the CXCR4 response to SDF-1 was concentration-dependent; MSC migration would increase with increasing extracellular SDF-1 concentration or increasing numbers of cell surface receptors. Nevertheless, CXCR4 expression was rare on the surface of MSCs (3.9% of cells), despite the presence of non-activated receptors in 83–98% of MSCs. Thus, mobilization of internal CXCR4 may increase MSC migration ability and improve their therapeutic efficacy. The endothelial nitric oxide synthase/nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate pathway upregulated SDF-1α secretion and CXCR4 expression on the surface of MSCs after SCI.

Interaction of SDF-1 with CXCR4 resulted in activation of G-protein-coupled phospholipase C and PI3K pathways, as well as the activated protein kinase C pathway. SDF-1 chemotaxis is associated with atypical protein kinase C-zeta subtype. However, protein kinase C-zeta is not directly activated by phospholipase C, but is activated indirectly by diacylglycerol and second messengers such as ceramide and phosphatidic acid, or by the PI3K/Akt pathway, leading to activation of downstream signaling molecules such as proline-rich tyrosine kinase 2, extracellular signal-regulated kinase and the NF-kB pathway. In addition, an upstream signaling molecule activated the downstream Janus kinase/signal transducer and activator of transcription and extracellular signal-regulated kinase pathways, and controlled focal adhesion kinase and paxillin activation and expression. Interaction between intracellular focal adhesion kinase/Src regulated the downstream cascade reaction and promoted human MSC migration.

**Monocyte chemoattractant protein-1 (MCP-1)**
MCP-1 belongs to the CC subfamily of chemokines and exerts its effects by binding to CC chemokine receptor 2.
Baek et al.\[^{40}\] reported that MSCs could express CC chemokine receptor 2 mRNA, but did not express CC chemokine receptor 2 protein because of the lack of an inducer in the medium. Astrocytes in the SCI region have been shown to secrete MCP-1, leading to increased MCP-1 levels in the serum\[^{53-54}\]. Wang et al.\[^{55}\] reported that MCP-1 contributed to MSC migration to the ischemic region, and CC chemokine receptor 2 is expressed on the surface of MSCs. Upregulated MCP-1 expression thus affected MSC migration by interacting with CC chemokine receptor 2.

Using MSCs transfected with a vector expressing a truncated version of FROUNT (DN-FROUNT), Belema-Bedada et al.\[^{56}\] reported that binding of activated CC chemokine receptor 2 to FROUNT triggered the PI3K-Rac pathway, induced cytoskeletal changes, produced pseudopodia, and promoted MSC migration after MCP-1 stimulation. When DN-FROUNT competes with endogenous FROUNT for CC chemokine receptor 2 binding and acts as a dominant-negative effector of CC chemokine receptor 2-mediated chemotaxis. The CC chemokine receptor 2/FROUNT/PI3K/Rac pathway could thus promote MSC migration.

MCP-3

MCP-3 is a member of the CC-chemokine family that exerts various chemotactic effects by binding to its receptors CC chemokine receptors 2, 3 and 5. Ma et al.\[^{57}\] reported that MCP-3 expression was significantly increased at 1 day after SCI, compared to after 7 days. Interactions between CC chemokine receptors 3 and 5 and their ligand regulated targeted MSC migration\[^{47}\], but this chemotaxis was weak compared to that stimulated by SDF-1 under similar conditions. Schenk et al.\[^{58}\] failed to verify the promotion of MSC migration by interactions between MCP-3 and CC chemokine receptor 1 or CC chemokine receptor 2; nevertheless, Belema-Bedada et al.\[^{56}\] believed that MCP-3 exerted its effects by activating CC chemokine receptor 2. MCP-3 can also act via the above-mentioned CC chemokine receptor 2/FROUNT/PI3K/Rac pathway. Further investigations are therefore needed to determine if upregulated MCP-3 exerts chemotaxis by one or two receptors.

**DISCUSSION**

In summary, expression levels of various cytokines and chemokines and their corresponding receptors are upregulated after SCI. These factors participate in targeted MSC migration, together with numerous signaling molecules in the *in vivo* microenvironment. All these factors are interlinked to produce a signaling network able to induce targeted MSC migration *in vivo*. However, few recent studies have reported direct evidence for the promotion of targeted MSC migration by chemokines following SCI.

Current studies addressing the mechanisms of MSC migration have provided theoretical evidence to improve our understanding of the pathological changes and signaling molecule transduction occurring during MSC migration. TNF-α can mediate MSC migration through its specific receptor. TNF-α binding to its receptors results in receptor activation, activation of NF-κB-inducing kinase via an adaptor protein, and triggering of the NIK/κB kinase/κB-κB pathway, resulting in κB complex degradation. Activated NF-κB subsequently enters the nucleus and induces various genes, including genes for cytokines, chemokines and adhesion factors\[^{13}\]. Moreover, interactions between activated TNF receptors and ligands can activate various transcription factors, including c-Jun, NF-κB and ATF-2\[^{13, 30}\] by activating MEKK1-MKK4/7-c-Jun NH2-terminal kinases and the MEKK1-MKK3/6-P38 pathway\[^{25}\], as well as promoting the expression of genes for products such as enzymes and receptors, including CC chemokine receptor 3, CC chemokine receptor 4 and intercellular adhesion molecule 1\[^{12, 14}\] in MSCs, and responding to surrounding inducers. NF-κB plays an important role in signal transduction. TNF-α mediates NF-κB activation and intranuclear transfer\[^{13}\], and chemotaxis by SDF-1 associated with NF-κB\[^{52}\]. In accordance with the NF-κB activation pathway, NIK caused MEKK1 activation resulting in κB kinase phosphorylation, thus linking TNF-α downstream signaling molecules. Moreover, the p21-activated kinase, Akt and germinal center kinase pathways could activate MEKK1 and NIK kinases, and induce c-Jun NH2-terminal kinases and NF-κB activation. Second, as shown in Figure 1, the chemotaxis induced by many cytokines and chemokines was confirmed by PI3K/Akt pathway experiments. Interactions between ligands and receptors could directly or indirectly trigger PI3K and further activate downstream signaling molecules, including Akt and protein kinase C, as well as the Rho family member Rac, resulting in cascade reactions in the cytoplasm and nucleus, and mediating MSC activity\[^{18, 22, 25-26, 35-36, 41-42, 52, 56}\]. The PI3K/Rac pathway is important\[^{26, 29, 42, 56}\]. The regulation by Rac of the downstream signaling molecules extracellular signal-regulated kinase and protein kinase C and the c-Jun NH2-terminal kinase pathway could induce nuclear gene expression and protein synthesis, resulting in MSC migration. It is assumed that the factors that trigger the PI3K/Akt pathway could activate NF-κB and control MSC migration activity.
SDF-1/CXCR4 chemotaxis has been a focus of attention. Previous studies found that SDF-1/CXCR4 mediated MSC migration to the bone marrow\textsuperscript{[2, 45]}. Intracellular signaling molecules, such as endothelial nitric oxide synthase/nitric oxide guanylate cyclase/cyclic guanosine monophosphate pathway, adjusted SDF-1/CXCR4 expression on the surface of MSCs. In addition, interaction between SDF-1 and CXCR4 activated PI3K and the phospholipase C pathway, the protein kinase C and Akt pathways, and c-Jun NH\textsubscript{2}-terminal kinases and extracellular signal-regulated kinase signaling molecules, as well as adjusting genetic transcription and protein expression\textsuperscript{[24, 42, 51-52]}.

SDF-1/CXCR4 could induce MSC migration, but although CXCR4 was expressed in most MSCs, few MSCs demonstrated surface expression of CXCR4\textsuperscript{[45]}; thus limiting SDF-1/CXCR4 chemotaxis. Further studies are needed to clarify this issue. Increasing cell surface CXCR4 expression could enhance the effects of cell therapy.

This study reviewed the roles of cytokines and chemokines in MSC migration to damaged regions following SCI, including the signal conduction mechanisms involved in MSC migration. The PI3K pathway, extracellular signal-regulated kinase pathway and NF-\kappa B in particular, appear to play important roles in cytokine and chemokine-regulated MSC migration following SCI.

**Funding:** This project was funded by the National Natural Science Foundation of China (Establishment of goat models of ischemic injury via corticospinal tract projection tract and action mechanism of MPA1B axon guidance during BMSC migration in the spinal cord), No. 30972153.

**Author contributions:** Longyun Li participated in study concept and design, and manuscript writing. Maoguang Yang was in charge of data collection. All authors provided data and ensured the integrity of the data. Weihua Wang and Xiaoyu Yang were in charge of manuscript authorization, obtained funding, and served as a principle investigator.

**Conflicts of interest:** None declared.

**REFERENCES**

[1] Satake K, Lou J, Lenke LG. Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine (Phila Pa 1976). 2004;29(18):1971-1979.

[2] Zhang J, Gong JF, Zhang W, et al. Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J Biomed Sci. 2008;15(5):585-594.

[3] Le Blanc K. Immunosupulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5(6):485-489.

[4] Pal R, Gopinath C, Rao NM, et al. Functional recovery after transplantation of bone marrow-derived human mesenchymal stromal cells in a rat model of spinal cord injury. Cytotherapy. 2010;12(6):792-806.

[5] Li H, Wen Y, Luo Y, et al. Transplantation of bone marrow mesenchymal stem cells into spinal cord injury: a comparison of delivery different times. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2010;24(2):180-184.

[6] Ghirnikar RS, Lee YL, Eng LF. Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J Neurosci. 2000;59(1):63-73.

[7] Fraidakis MJ, Kiyotani T, Pernold K, et al. Recovery from spinal cord injury in tumor necrosis factor-alpha, signal transducers and activators of transcription 4 and signal transducers and activators of transcription 6 null mice. Neuroreport. 2007;18(2):185-189.

[8] Genovese T, Mazzon E, Crisafulli C, et al. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock. 2008;29(1):32-41.

[9] Pan W, Zhang L, Liao J, et al. Selective increase in TNF alpha permeation across the blood-spinal cord barrier after SCI. J Neuroimmunol. 2003;134(1-2):111-117.

[10] Gutiérrez-Fernández M, Rodríguez-Frutos B, Alvarez-Grech J, et al. Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats. Neuroscience. 2011;175:394-405.
[11] Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108(12):3938-3944.

[12] Fu X, Han B, Cai S, et al. Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor-alpha and its possible role in wound healing. Wound Repair Regen. 2009;17(2):185-191.

[13] Segers VF, Van Riet I, Andries LJ, et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am J Physiol Heart Circ Physiol. 2006;290(4):1370-1377.

[14] Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007;25(7):1737-1745.

[15] Liu Y, Figley S, Spratt SK, et al. An engineered transcription factor which activates VEGF-A enhances recovery after spinal cord injury. Neurobiol Dis. 2010;37(2):384-393.

[16] Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007;177(3):489-500.

[17] Bayley C, Shuttleworth CA, Kielty CM. Neurphilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells. Blood. 2010;111(2):29-40.

[18] Lee SH, Lee YJ, Song CH, et al. Role of FAK phosphorylation in hypoxia-induced hMSCS migration: involvement of VEGF as well as MAPKs and eNOS pathways. Am J Physiol Cell Physiol. 2008;294(8):C847-856.

[19] Shimamura M, Sato N, Sata M, et al. Expression of hepatocyte growth factor and c-Met after spinal cord injury in rats. Brain Res. 2007;1151:188-194.

[20] Kitamura K, Iwanami A, Nakamura M, et al. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res. 2007;85(11):2332-2342.

[21] Son BR, Marquez-Curtis LA, Kucia M, et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006;24(5):1254-1264.

[22] Royal I, Lamarche-Vane N, Lamorte L, et al. Activation of cdc42, rac, Pak, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell. 2000;11(5):1709-1725.

[23] Mohamadnejad M, Sohail MA, Watanabe A, et al. Adenosine inhibits chemotaxis and induces hepatocyte-specific genes in bone marrow mesenchymal stem cells. Hepatology. 2010;51(3):963-973.

[24] Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704-1709.

[25] Gentili N, Busacca M, Di Francesco S, et al. PI3K/Akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors. Mol Hum Reprod. 2007;13(5):317-322.

[26] Kim EK, Tucker DF, Yun SJ, et al. Linker region of Akt1 protein kinase Balpa mediates platelet-derived growth factor-induced translocation and cell migration. Cell Signal. 2008;20(11):2030-2037.

[27] Wu QH, Chen WS, Chen QX, et al. Changes in the expression of platelet-derived growth factor in astrocytes in diabetic rats with spinal cord injury. Chin Med J (Engl). 2010;123(12):1577-1581.

[28] Xiyang YB, Liu S, Liu J, et al. Roles of platelet-derived growth factor-B expression in the ventral horn and motor cortex in the spinal cord-hemisected shemus monkey. J Neurotrauma. 2009;26(2):275-287.

[29] Hata N, Shinojima N, Gumin J, et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010;66(1):144-156.

[30] Kang YJ, Jeon ES, Song HY, et al. Role of c-Jun N-terminal kinase in the PDGF-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. J Cell Biochem. 2005;95(6):1135-1145.

[31] Monypenny J, Zicha D, Higashida C, et al. Cdc42 and Rac family GTPases regulate mode and speed but not direction of primary fibroblast migration during platelet-derived growth factor-dependent chemotaxis. Mol Cell Biol. 2009;29(10):2730-2747.

[32] Meij S, Timmers L, Pears D, et al. Basic fibroblast growth factor promotes neuronal survival but not behavioral recovery in the transected and Schwann cell implanted rat thoracic spinal cord. J Neurotrauma. 2004;21(10):1415-1430.

[33] Liu WG, Wang ZY, Huang ZS. Bone marrow-derived mesenchymal stem cells expressing the bFGF transgene promote axon regeneration and functional recovery after spinal cord injury in rats. Neurol Res. 2011;33(7):686-693.

[34] Liu L, Pei FX, Tang KL, et al. Effect of basic fibroblast growth factor on change of caspase 3 gene expression after distractive spinal cord injury in rats. Zhonghua Yi Xue Za Zhi. 2005;85(20):1424-1427.

[35] Schmidt A, Ladage D, Schinköthe T, et al. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells. 2006;24(7):1750-1758.

[36] Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905-2927.

[37] Hung KS, Tsai SH, Lee TC, et al. Gene transfer of insulin-like growth factor-I providing neuroprotection after spinal cord injury in rats. J Neurosurg Spine. 2007;6(1):35-46.

[38] Koopmans GC, Brans M, Gómez-Pinilla F, et al. Circulating insulin-like growth factor I and functional recovery from spinal cord injury under enriched housing conditions. Eur J Neurosci. 2006;23(4):1035-1046.

[39] Umemura T, Harada N, Kitamura T, et al. Limaprost reduces motor disturbances by increasing the production of insulin-like growth factor I in rats subjected to spinal cord injury. Transl Res. 2010;156(5):292-301.

[40] Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med. 2011;43(10):596-603.
[41] Haider HKh, Jiang S, Idris NM, et al. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1 alpha/CXCR4 signaling to promote myocardial repair. Circ Res. 2008;103(11):1300-1308.

[42] Li Y, Yu X, Lin S, et al. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem Biophys Res Commun. 2007;356(3):780-784.

[43] Knerlich-Lukoschus F, von der Ropp-Brenner B, Lucius R, et al. Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J Neurosurg Spine. 2011;14(5):583-597.

[44] Brenner S, Whiting-Theobald N, Kawai T, et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells. 2004;22(7):1128-1133.

[45] Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004;104(9):2643-2645.

[46] Tyselling VM, Mithal D, Sahni V, et al. SDF1 in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal cord injury. J Neuroinflammation. 2011;8:16.

[47] Song CH, Honnou M, Furuoka H, et al. Identification of chemotactic factors involved in the migration of bone marrow-derived mesenchymal stem cells to brain lesions caused by prions. J Virol. 2011;85(21):11069-11078.

[48] Tsai LK, Wang Z, Munasinghe J, et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke. 2011;42(10):2932-2939.

[49] Cui X, Chen J, Zacharek A, et al. Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke. Stem Cells. 2007;25(11):2777-2785.

[50] Wang Y, Deng Y, Zhou GQ. SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res. 2008;1195:104-112.

[51] Wang YP, Tang JM, Guo LY, et al. Adenovirus-mediated stromal cell-derived factor-1 alpha gene transfer promotes mesenchymal stem cell migration. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(7):1190-1194.

[52] Gao H, Priebe W, Gild J, et al. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009;27(4):857-865.

[53] Liu SQ, Ma YG, Peng H, et al. Monocyte chemoattractant protein-1 level in serum of patients with acute spinal cord injury. Chin J Traumatol. 2005;8(4):216-219.

[54] Pineau I, Sun L, Bastien D, et al. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav Immun. 2010;24(4):540-553.

[55] Wang L, Li Y, Chen X, et al. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology. 2002;7(2):113-117.

[56] Belema-Bedada F, Uchida S, Martire A, et al. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell. 2008;2(6):566-575.

[57] Ma M, Wei T, Boring L, et al. Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res. 2002;68(6):691-702.

[58] Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells. 2007;25(1):245-251.

(Edited by He XJ, Ni SB/Qiu Y/Song LP)